Affordable Access

Publisher Website

Precise Chemodynamic Therapy of Cancer by Trifunctional Bacterium-Based Nanozymes.

  • Zhang, Weiyun1, 2
  • Liu, Jiawei3
  • Li, Xuyu2
  • Zheng, Yue4
  • Chen, Lianfu5
  • Wang, Dongdong3
  • Foda, Mohamed Frahat1, 6
  • Ma, Zhaoyu1, 3
  • Zhao, Yanli3
  • Han, Heyou1, 2
  • 1 State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, PR China. , (China)
  • 2 College of Science, Huazhong Agricultural University, Wuhan 430070, PR China. , (China)
  • 3 Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, 637371 Singapore. , (Singapore)
  • 4 Key Laboratory of Urban Pollutant Conversion, Institute of Urban Environment, Chinese Academy of Sciences, Xiamen 361021, PR China. , (China)
  • 5 South China Botanical Garden, Chinese Academy of Sciences, Guangzhou 510520, PR China. , (China)
  • 6 Department of Biochemistry, Faculty of Agriculture, Benha University, Moshtohor, Toukh 13736, Egypt. , (Egypt)
Published Article
ACS Nano
American Chemical Society
Publication Date
Dec 01, 2021
DOI: 10.1021/acsnano.1c05605
PMID: 34851608


Chemodynamic therapy (CDT) destroys cancer cells by converting H2O2 or O2 into reactive oxygen species (ROS), but its therapeutic efficacy is restricted by the antioxidant capacity of tumor. Previous solutions focused on strengthening the nanodrugs with the ability to increase ROS production or weaken the antioxidant capacity of cancer cells. Conversely, we here develop a mild nanodrug with negligible side effects. Specifically, the [email protected] nanozyme decorated on a bacterial surface ([email protected]) is reported to achieve precise CDT. Due to the tumor targeting ability of bacteria and catalytic property of [email protected] nanozyme under acidic conditions, this nanosystem can release ROS to tumor cells effectively. In addition, the interferon gamma released by T cells specifically decreases the intracellular reductants in tumor cells, while having no obvious effect on normal cells. Therefore, a low dose of [email protected] achieves a satisfactory therapeutic efficacy to tumor cells and is nontoxic to normal cells even at their acidic components. This nanosystem enables CDT and immunotherapy to mutually benefit and improve by each other, providing a promising strategy to achieve high anticancer efficacy even with a low dose usage.

Report this publication


Seen <100 times